WellBiome® clinical trial on surgical outcomes

AI SummaryClose X

OptiBiotix Health plc has initiated a clinical study with Hull University Teaching Hospital NHS Trust to assess the impact of its WellBiome prebiotic on cardiac surgery outcomes and potential NHS cost savings. This double-blind, placebo-controlled study will involve up to 60 patients and evaluate the effects of six-week pre-operative supplementation on intensive care time, hospital stay duration, and post-operative complications, with a cost savings analysis also included. The company highlights WellBiome's patented mineral-enriched prebiotic fibre complex, designed to enhance gut microbiome diversity and offering various health benefits, as a response to growing consumer interest in gut health.

Disclaimer*

UK 100

Latest directors dealings